American Society of Clinical Oncology

SHERPA: White

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. O'Reilly
    O'Reilly
  4. Saltz
    Saltz
  5. Bajorin
    Bajorin
  6. Kris
    Kris
  7. Hudis
    Hudis
  8. Morris
    Morris
  9. Rosenberg
    Rosenberg
  10. Robson
    Robson

Groups

  1. Department of Medicine (6392)
  2. Solid Tumor Oncology Division (5533)
  3. Survivorship Research (1994)
  4. Genitourinary Oncology Service (1767)
  5. Surgery (1636)
  6. Epidemiology and Biostatistics (1493)
  7. GSK Faculty (1388)
  8. Population Sciences Research Program (1376)
  9. Gastrointestinal Oncology Service (1352)
  10. Hematologic Malignancies, Division of (1277)
Search Within
Formats
  1. Meeting Abstract (6334)
  2. Journal Article (2572)
  3. Editorial (74)
  4. Review (65)
  5. Guidelines (54)
  6. Correspondence (48)
  7. Miscellaneous (4)
  8. Conference Paper (3)
Groups
  1. Department of Medicine (6392)
  2. Solid Tumor Oncology Division (5533)
  3. Survivorship Research (1994)
  4. Genitourinary Oncology Service (1767)
  5. Surgery (1636)
  6. Epidemiology and Biostatistics (1493)

More Groups

People
  1. Robert Motzer (451)
  2. Howard Scher (334)
  3. Eileen O'Reilly (306)
  4. Leonard Saltz (283)
  5. Dean Bajorin (280)
  6. Mark Kris (253)

More People

Years
  1. 2025 (262)
  2. 2024 (554)
  3. 2023 (580)
  4. 2022 (554)
  5. 2021 (504)
  6. 2020 (539)

More Years

Publications
  1. Journal of Clinical Oncology (8683)
  2. JCO Precision Oncology (170)
  3. Journal of Oncology Practice (124)
  4. American Society of Clinical Oncology Educational Book (112)
  5. JCO Clinical Cancer Informatics (53)
  6. JCO Oncology Practice (6)

More Publications

Results (9154)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Updated results from the trastuzumab deruxtecan (T-DXd) 5.4 mg/kg triplet combination of DESTINY-Gastric03 (DG-03): First-line (1L) T-DXd with fluoropyrimidine (FP) and pembrolizumab in advanced/metastatic HER2-positive (HER2+) esophageal adenocarcinoma, gastric cancer (GC), or gastroesophageal junction adenocarcinoma (GEJA)
    Meeting Abstract

    Janjigian, Y. Y.; Van Laarhoven, H. W. M.; Rha, S. Y.; Kozlov, V.; Oh, D. Y.; Gravina, A.; Rapatoni, L.; Shoji, H.; Hofheinz, R. D.; Chen, L. T.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • The prognostic value of HER2 gene dosage and heterogeneity at a single-cell resolution in gastroesophageal adenocarcinoma
    Meeting Abstract

    Parashar, Y.; Culnane, L.; Remland, J.; Nambiar, C.; Yuan, C.; Nasta, S.; Bard, A.; Park, H.; Klempner, S. J.; Giannakis, M.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Concordance between human epidermal growth factor receptor 2 (HER2) status by immunohistochemistry (IHC) and next-generation sequencing (NGS) in tissue and blood samples from gastric and gastroesophageal junction cancers (GC/GEJC)
    Meeting Abstract

    Maron, S. B.; Burke, K.; Gupta, P.; Sarlo, K.; Tesic-Schnell, M.; Woo, M. S. A.; Klempner, S. J.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Zanidatamab dose optimization in patients with HER2-positive biliary tract cancer (BTC)
    Meeting Abstract

    Trueman, S.; Wu, L.; Girgis, S.; Vaidya, K.; Meric-Bernstam, F.; Harding, J. J.; Pant, S.; Zhao, Y.; Garfin, P. M.; Iannone, R.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Molecular and clinical determinants of targeted therapy (TT) outcomes in biliary tract cancer (BTC): Analysis of a prospectively maintained next generation sequencing (NGS) biorepository
    Meeting Abstract

    Cowzer, D.; Walch, H. S.; Atri, P.; Shah, F.; Huq, R.; Khalil, D. N.; Park, W.; Yeh, R.; Do, R. K. G.; Basturk, O.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Association between immune-related adverse events and prognosis after immune checkpoint inhibitor in hepatocellular carcinoma: A meta-analysis and systematic review
    Meeting Abstract

    Hwang, S. Y.; Rezaee-Zavareh, M. S.; Attia, A. M.; Kaymen, E.; Tran, N. H.; Abou-Alfa, G. K.; Singal, A.; Yang, J. D.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Influence of preoperative Lynch syndrome diagnosis on surgery in patients with colorectal cancer
    Meeting Abstract

    Abbass, M. A.; Nielsen Young, S. M.; Russell, E. M.; Esplin, E.; Pineda-Alvarez, D.; Heald, B.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Adagrasib (Ada) + cetuximab (Cetux) for KRAS(G12C)-mutated metastatic colorectal cancer (mCRC): Longer follow-up analysis from KRYSTAL-1
    Meeting Abstract

    Yaeger, R.; Uboha, N. V.; Klempner, S. J.; Bekaii-Saab, T. S.; Sabari, J. K.; Barve, M. A.; Saltzman, J. N.; Peguero, J. A.; Paulson, A. S.; Jänne, P. A.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Risk of residual tumor following removal of a malignant colorectal polyp with high-risk features
    Meeting Abstract

    Tawantanakorn, T.; Bektas, A. B.; Hill, M.; Widmar, M.; Karagkounis, G.; Wei, I. H.; Smith, J. J.; Pappou, E.; Nash, G. M.; Paty, P.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Association between adjuvant component of perioperative chemotherapy and survival outcomes in resected gastric cancer (GC)
    Meeting Abstract

    Sreeram, A.; Yeh, C.; Toumbacaris, N.; Capanu, M.; Shimada, S.; Gu, P.; Janjigian, Y. Y.; Ilson, D. H.; Strong, V. E.; Ku, G. Y.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save